Values as of: 2024-10-30
COMMON STOCK | Medical Devices |
Last Closing
USD 18.78Change
0.00 (0.00)%Market Cap
USD 4.94BVolume
N/AAnalyst Target
N/AVerdict
Verdict
Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. The company offers anaesthesia, and patient monitoring and diagnostics products. The company also offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, cystoscopes, and display units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products consisting of airway management and anaesthesia products, such as bronchoscopes, video laryngoscopes, double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers extrication collars, CPR breathing barriers, video laryngoscopes, and training manikins. The company was founded in 1937 and is headquartered in Ballerup, Denmark.
Company Website : https://www.ambu.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| SEMHF | Siemens Healthineers AG |
N/A |
USD 63.76B |
| SMMNY | Siemens Healthineers AG ADR |
-0.42 (-1.58%) |
USD 62.17B |
| RYLPF | Koninklijke Philips N.V |
N/A |
USD 29.83B |
| SONVF | Sonova Holding AG |
N/A |
USD 22.04B |
| SNWV | SANUWAVE Health Inc |
-1.50 (-7.89%) |
USD 20.67B |
| SNNUF | Smith & Nephew plc |
+0.01 (+0.03%) |
USD 12.78B |
| WILLF | Demant A/S |
N/A |
USD 8.72B |
| GNGBF | Getinge AB |
N/A |
USD 5.12B |
| AMBFF | Ambu A/S |
N/A |
USD 4.94B |
| GGNDF | GN Store Nord A/S |
N/A |
USD 3.10B |
N/A
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 22.75% | 71% | C- | 68% | D+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 22.75% | 72% | C | 69% | C- | ||
| Trailing 12 Months | |||||||
| Capital Gain | 92.22% | 83% | B | 83% | B | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 92.22% | 83% | B | 83% | B | ||
| Trailing 5 Years | |||||||
| Capital Gain | 19.92% | 68% | D+ | 69% | C- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 19.92% | 68% | D+ | 69% | C- | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 7.79% | 52% | F | 50% | F | ||
| Dividend Return | 7.88% | 52% | F | 47% | F | ||
| Total Return | 0.09% | 17% | F | 4% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 57.81% | 56% | F | 47% | F | ||
| Risk Adjusted Return | 13.63% | 58% | F | 47% | F | ||
| Market Capitalization | 4.94B | 91% | A- | 86% | B+ | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company has under performed its peers on annual average total returns in the past 5 years.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
